Tizanidne Hydrochloride Capsule
Product Images NDC 63629-8872

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidne Hydrochloride (NDC 63629-8872). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636298872)

Label for Tizanidine Hydrochloride Capsules, 4 mg, containing 150 capsules. The label includes the NDC 63629-8872-1 and states the product is prescription only (Rx only). It is relabeled by Bryant Ranch Prepack, Inc., Burbank, CA, and features storage instructions along with a note that the capsules are not interchangeable with tizanidine tablets or Zanaflex tablets. The BRP Pharmaceuticals logo appears on the label.*

FDA Label Image

Tiz01 (Tiz01)

Chemical structure diagram of Tizanidine Hydrochloride showing its molecular framework including a chlorinated benzene ring fused to a thiazole and a pyrrolidine group.*

FDA Label Image

Tiz02 (Tiz02)

A line graph depicting plasma Tizanidine concentration (ng/mL) over time (hours) following dosing. The graph compares four groups: 2 x 4 mg Tizanidine tablets with food, 2 x 4 mg Tizanidine tablets without food, 2 x 4 mg Tizanidine capsules with food, and 2 x 4 mg Tizanidine capsules without food, showing differences in absorption and concentration profiles up to 24 hours post-dose.*

FDA Label Image

Tiz03 (Tiz03)

A line graph showing improvement in Ashworth Score over 6 hours post-dose for 16 mg tizanidine, 8 mg tizanidine, and placebo. The graph plots improvement scores on the vertical axis and hours post-dose on the horizontal axis. Data points include error bars indicating variability at each hour.*

FDA Label Image

Tiz04 (Tiz04)

A line chart comparing improvement in Ashworth Score between tizanidine (mean dose 28.8 mg) and placebo groups at three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). Tizanidine data points show greater improvement (lower scores) versus placebo, with error bars indicating variability.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.